Imagining a Biotech Future

Right now, scientists can read your entire genetic code for less than a high-end phone. In one lab, a doctor tweaks a single DNA letter to erase a disease. In another, a chef grills a burger grown in a steel tank, not on a farm. The question is: whose future are we actually engineering?

The tools behind those breakthroughs are quietly fusing into something bigger: biology as a programmable platform. CRISPR is no longer a one-off lab trick; paired with AI models that learned from 200 million protein structures, it’s turning cells into designable units. Instead of guessing which molecule might work, algorithms propose thousands, simulate their behavior, and route only the most promising to the bench.

That same loop is creeping into agriculture and materials. Startups are engineering microbes to brew spider-silk-like fibers, coastal cities are testing salt-tolerant crops, and pharma companies are exploring treatments tuned to a person’s specific mutation, not just their diagnosis. The cost curves look less like medicine and more like computing: every year, more power, less price, more people able to participate—and more ways the technology can be misused or misaligned.